ARTICLE | Clinical News

Regulus doubles on interim HCV data

October 23, 2014 2:50 AM UTC

Regulus Therapeutics Inc. (NASDAQ:RGLS) surged $6.98 (103.1%) to $13.75 on Wednesday after announcing interim results from a Phase I trial in which a single 2 mg/kg injection of antisense therapy RG-101 led to significant and sustained viral reductions in HCV-infected patients.

The company reported that RG-101 monotherapy produced mean viral load reduction of 4.1 log10 at day 29 in 14 HCV patients with genotypes 1, 3 or 4. Six of the 14 treated patients (43%) had no detectable HCV RNA at day 29. The trial included 8 patients who were treatment-naive and 6 who had relapsed after treatment with an interferon-containing regimen. ...